SMT202500001T1 - Nuovo uso di una combinazione di un bloccante del recettore dell’angiotensina (arb) con un inibitore dell’endopeptidasi neutra (nepi) - Google Patents

Nuovo uso di una combinazione di un bloccante del recettore dell’angiotensina (arb) con un inibitore dell’endopeptidasi neutra (nepi)

Info

Publication number: SMT202500001T1
Authority: SM; San Marino
Prior art keywords: nepi; arb; combination; receptor blocker; new use
Prior art date: 2013-08-26

Application number

SM20250001T

Other languages

English (en)

Inventor

Victor Chengwei Shi

Martin Lefkowitz

Adel Remond Rizkala

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-26

Filing date

2014-08-26

Publication date

2025-03-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202500001(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-08-26 Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en

2014-08-26 Application filed by Novartis Ag filed Critical Novartis Ag

2025-03-12 Publication of SMT202500001T1 publication Critical patent/SMT202500001T1/it

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

SM20250001T 2013-08-26 2014-08-26 Nuovo uso di una combinazione di un bloccante del recettore dell’angiotensina (arb) con un inibitore dell’endopeptidasi neutra (nepi) SMT202500001T1 (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/US2013/056680 WO2015030711A1 (en)	2013-08-26	2013-08-26	New use
US201461972933P	2014-03-31	2014-03-31
EP23202190.7A EP4321157B1 (en)	2013-08-26	2014-08-26	New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)

Publications (1)

Publication Number	Publication Date
SMT202500001T1 true SMT202500001T1 (it)	2025-03-12

Family

ID=51494327

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20250001T SMT202500001T1 (it)	2013-08-26	2014-08-26	Nuovo uso di una combinazione di un bloccante del recettore dell’angiotensina (arb) con un inibitore dell’endopeptidasi neutra (nepi)

Country Status (16)

Country	Link
US (2)	US20160213646A1 (it)
EP (4)	EP3038654B1 (it)
JP (1)	JP6097888B2 (it)
CY (1)	CY1122531T1 (it)
DK (3)	DK4321157T3 (it)
ES (3)	ES2767084T3 (it)
FI (2)	FI3626270T3 (it)
HR (3)	HRP20240034T1 (it)
HU (3)	HUE069419T2 (it)
LT (3)	LT4321157T (it)
PL (3)	PL4321157T3 (it)
PT (3)	PT4321157T (it)
RS (3)	RS59816B1 (it)
SI (3)	SI3038654T1 (it)
SM (1)	SMT202500001T1 (it)
WO (1)	WO2015028941A1 (it)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT4321157T (lt)	2013-08-26	2025-01-10	Novartis Ag	Naujas angiotenzino receptoriaus blokatoriaus (arb) ir neutralios endopeptidazės inhibitoriaus (nepi) derinio panaudojimas
US10562866B2 (en) *	2015-02-06	2020-02-18	Mylan Laboratories Limited	Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
US20180140579A1 (en) *	2015-05-29	2018-05-24	Novartis Ag	Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) *	2015-06-30	2017-01-11	深圳信立泰药业股份有限公司	一种用于心衰治疗的药物组合物及其制备方法
WO2017036420A1 (zh) *	2015-09-06	2017-03-09	常州方楠医药技术有限公司	含沙库比曲和缬沙坦的药用组合物及其制备方法
CN107510653A (zh) *	2016-06-17	2017-12-26	常州爱诺新睿医药技术有限公司	一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
CN106491600A (zh) *	2015-09-06	2017-03-15	常州方楠医药技术有限公司	无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017042700A1 (en) *	2015-09-07	2017-03-16	Sun Pharmaceutical Industries Limited	Solid forms of valsartan and sacubitril
CN106580908A (zh) *	2015-10-16	2017-04-26	深圳信立泰药业股份有限公司	一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) *	2015-12-07	2017-12-22	南京正大天晴制药有限公司	一种制备lcz696的方法
CN108601741B (zh)	2016-02-03	2022-05-24	诺华股份有限公司	有机化合物的盖伦制剂
CN106176681A (zh) *	2016-08-25	2016-12-07	泰力特医药（湖北）有限公司	一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en)	2017-07-06	2022-07-12	Mankind Pharma Ltd.	Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2020039386A1 (en)	2018-08-23	2020-02-27	Novartis Ag	New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en)	2018-08-24	2020-02-27	Novartis Ag	New drug combinations
JP7316449B2 (ja) *	2019-09-20	2023-07-27	シェンヅェンサルブリスファーマシューティカルズカンパニーリミテッド	心不全治療におけるアンジオテンシンｉｉ受容体アンタゴニスト代謝産物とｎｅｐ阻害剤との複合体の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0443983T3 (da)	1990-02-19	1996-03-18	Ciba Geigy Ag	Acrylforbindelser
US5217996A (en)	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
DK0966282T3 (da) *	1997-01-10	2003-09-29	Merck & Co Inc	Anvendelse af angiotensin ll antagonister til behandling af symptomatisk hjerteinsufficiens
SI1467728T1 (sl)	2002-01-17	2008-02-29	Novartis Ag	Farmacevtski sestavki vkljucujoci valsartan in NEP inhibitorje
EP1631556A1 (en) *	2003-05-16	2006-03-08	Novartis AG	Pharmaceutical composition comprising valsartan
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
MY153730A (en)	2007-11-06	2015-03-13	Novartis Ag	Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
KR101807319B1 (ko)	2008-11-22	2017-12-11	제넨테크, 인크.	유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
PH12013500231A1 (en)	2010-08-24	2017-08-09	Novartis Ag	Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
RU2667643C2 (ru)	2012-08-24	2018-09-21	Новартис Аг	Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
LT4321157T (lt)	2013-08-26	2025-01-10	Novartis Ag	Naujas angiotenzino receptoriaus blokatoriaus (arb) ir neutralios endopeptidazės inhibitoriaus (nepi) derinio panaudojimas
EP3038653A1 (en) *	2013-08-26	2016-07-06	Novartis AG	New use

2014
- 2014-08-26 LT LTEP23202190.7T patent/LT4321157T/lt unknown
- 2014-08-26 HR HRP20240034TT patent/HRP20240034T1/hr unknown
- 2014-08-26 RS RS20200047A patent/RS59816B1/sr unknown
- 2014-08-26 SM SM20250001T patent/SMT202500001T1/it unknown
- 2014-08-26 LT LTEP19202854.6T patent/LT3626270T/lt unknown
- 2014-08-26 HR HRP20241763TT patent/HRP20241763T1/hr unknown
- 2014-08-26 FI FIEP19202854.6T patent/FI3626270T3/fi active
- 2014-08-26 PT PT232021907T patent/PT4321157T/pt unknown
- 2014-08-26 HU HUE23202190A patent/HUE069419T2/hu unknown
- 2014-08-26 JP JP2016537414A patent/JP6097888B2/ja active Active
- 2014-08-26 PT PT192028546T patent/PT3626270T/pt unknown
- 2014-08-26 PL PL23202190.7T patent/PL4321157T3/pl unknown
- 2014-08-26 US US14/914,005 patent/US20160213646A1/en not_active Abandoned
- 2014-08-26 RS RS20240031A patent/RS65037B1/sr unknown
- 2014-08-26 SI SI201431464T patent/SI3038654T1/sl unknown
- 2014-08-26 FI FIEP23202190.7T patent/FI4321157T3/fi active
- 2014-08-26 WO PCT/IB2014/064074 patent/WO2015028941A1/en not_active Ceased
- 2014-08-26 PT PT147617021T patent/PT3038654T/pt unknown
- 2014-08-26 SI SI201432099T patent/SI4321157T1/sl unknown
- 2014-08-26 PL PL19202854.6T patent/PL3626270T3/pl unknown
- 2014-08-26 DK DK23202190.7T patent/DK4321157T3/da active
- 2014-08-26 EP EP14761702.1A patent/EP3038654B1/en not_active Revoked
- 2014-08-26 EP EP24206614.0A patent/EP4512397A3/en active Pending
- 2014-08-26 PL PL14761702T patent/PL3038654T3/pl unknown
- 2014-08-26 RS RS20241359A patent/RS66371B1/sr unknown
- 2014-08-26 LT LTEP14761702.1T patent/LT3038654T/lt unknown
- 2014-08-26 ES ES14761702T patent/ES2767084T3/es active Active
- 2014-08-26 SI SI201432059T patent/SI3626270T1/sl unknown
- 2014-08-26 EP EP19202854.6A patent/EP3626270B1/en active Active
- 2014-08-26 HR HRP20200060TT patent/HRP20200060T1/hr unknown
- 2014-08-26 HU HUE14761702A patent/HUE047186T2/hu unknown
- 2014-08-26 EP EP23202190.7A patent/EP4321157B1/en active Active
- 2014-08-26 DK DK14761702.1T patent/DK3038654T3/da active
- 2014-08-26 DK DK19202854.6T patent/DK3626270T3/da active
- 2014-08-26 ES ES23202190T patent/ES3001196T3/es active Active
- 2014-08-26 ES ES19202854T patent/ES2968541T3/es active Active
- 2014-08-26 HU HUE19202854A patent/HUE064634T2/hu unknown
2020
- 2020-01-28 CY CY20201100075T patent/CY1122531T1/el unknown
- 2020-11-24 US US17/103,327 patent/US20210077461A1/en active Pending

Also Published As

Publication number	Publication date
WO2015028941A1 (en)	2015-03-05
CY1122531T1 (el)	2021-01-27
ES2968541T3 (es)	2024-05-10
RS65037B1 (sr)	2024-02-29
PT3038654T (pt)	2020-02-04
LT3038654T (lt)	2020-01-27
US20210077461A1 (en)	2021-03-18
EP3626270B1 (en)	2023-10-11
ES3001196T3 (es)	2025-03-04
SI3038654T1 (sl)	2020-02-28
LT3626270T (lt)	2024-01-25
EP3038654B1 (en)	2019-10-30
PL3038654T3 (pl)	2020-05-18
HRP20241763T1 (hr)	2025-03-14
DK3626270T3 (da)	2024-01-15
HRP20200060T1 (hr)	2020-04-03
LT4321157T (lt)	2025-01-10
EP4321157B1 (en)	2024-10-23
RS59816B1 (sr)	2020-02-28
JP2016528303A (ja)	2016-09-15
SI4321157T1 (sl)	2025-03-31
PL3626270T3 (pl)	2024-04-08
US20160213646A1 (en)	2016-07-28
JP6097888B2 (ja)	2017-03-15
HUE064634T2 (hu)	2024-04-28
HUE069419T2 (hu)	2025-03-28
PT3626270T (pt)	2024-01-11
PT4321157T (pt)	2025-01-08
ES2767084T3 (es)	2020-06-16
EP4512397A3 (en)	2025-05-14
EP3626270A1 (en)	2020-03-25
DK4321157T3 (da)	2024-12-16
RS66371B1 (sr)	2025-02-28
FI4321157T3 (fi)	2025-01-20
EP4321157A2 (en)	2024-02-14
EP4321157A3 (en)	2024-05-15
HRP20240034T1 (hr)	2024-03-29
EP4512397A2 (en)	2025-02-26
EP3038654A1 (en)	2016-07-06
DK3038654T3 (da)	2020-02-03
HUE047186T2 (hu)	2020-04-28
PL4321157T3 (pl)	2025-03-03
SI3626270T1 (sl)	2024-03-29
FI3626270T3 (fi)	2024-01-11

Publication	Publication Date	Title
PL4321157T3 (pl)	2025-03-03	Nowe zastosowanie kombinacji blokera receptora angiotensyny (arb) z inhibitorem neutralnej endopeptydazy (nepi)
EP2970340A4 (en)	2016-10-19	BETA-Lactamase INHIBITORS
EP2943204A4 (en)	2016-11-09	BETA-Lactamase INHIBITORS
EP2948450A4 (en)	2016-11-09	METALLOENZYMINHIBITORVERBINDUNGEN
LT2970272T (lt)	2019-04-25	Glikozidazės inhibitoriai
ZA201702252B (en)	2019-06-26	A selective inhibitor of prosphatidylinositol 3-kinase-gamma
PL2984871T3 (pl)	2021-01-11	Operacja pdcp w celu podwójnego połączenia
PL3068685T3 (pl)	2019-07-31	Przewłoka prowadząca elementu kotwicznego
PT3293176T (pt)	2021-03-03	Forma cristalina de um inibidor de pde4
GB201317609D0 (en)	2013-11-20	Inhibitor compounds
AP2015008621A0 (en)	2015-07-31	Substituted bisphenyl butanoic nep 'neutral endopeptidase' inhibitors
ZA201506516B (en)	2016-06-29	Hdac inhibitors
GB201300357D0 (en)	2013-02-20	Plumbing diverter component
IL240019A0 (en)	2015-09-24	Estrogen receptor inhibitors
EP3084587A4 (en)	2017-08-09	Determining image rescale factors
HUE070532T2 (hu)	2025-06-28	NMDA antagonista prodrugok
GB201308077D0 (en)	2013-06-12	Biomarkers
GB201313664D0 (en)	2013-09-11	Bcl-3 inhibitors
PL3014029T3 (pl)	2018-11-30	Zespół syfonu
IL245386A0 (en)	2016-06-30	A crystalline beta-lactamase inhibitor
SG11201509142UA (en)	2015-12-30	Detecting endocrine disrupting compounds
GB201321328D0 (en)	2014-01-15	Inhibitor compounds
GB201305503D0 (en)	2013-05-08	Inhibitor
GB201320835D0 (en)	2014-01-08	HIF inhibitors
GB201307906D0 (en)	2013-06-12	Corrosion inhibitor